|
Cambronero F., Vilchez J.A., García-Honrubia A., Ruiz-Espejo F., Moreno V., Hernández-Romero D., Bonacasa B., González-Conejero R., de la Morena G., Martínez P., Climent V., Valdés M., Marín F. Plasma levels of Von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thrombosis Research. July 2010. 126. 10.1016/j.thromres.2010.01.010
AÑO: 2010; IF: 2.372
|
20156645
|
López-Cuenca A, Marín F, Roldán V, González-Conejero R, Hernández-Romero D, Valdés M, Lip GY. Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Ann Med. 2010 Dec;42(8):562-75. doi: 10.3109/07853890.2010.507601. Epub 2010 Aug 4. Review. PubMed PMID: 20681943.
AÑO: 2010; IF: 4.323
|
|
Caballero L., Climent V., Hernández-Romero D., Quintanilla M.A., de la Morena G., Marín F. Enzyme replacement therapy in fabry disease: Influence on cardiac manifestations. Current Medicinal Chemistry. 2010. 17:1679-1689. 10.2174/092986710791111297
AÑO: 2010; IF: 4.63
|
|
Lip G.Y.H., Huber K., Andreotti F., Arnesen H., Airaksinen J.K., Cuisset T., Kirchhof P., Marín F. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary-a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. June 2010. 31:1311-1318. 10.1093/eurheartj/ehq117
AÑO: 2010; IF: 10.052
|
|
López-Cuenca A, Marín F, Roldán V, Climent VE, Valdés M, Lip GY. Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with ischemic heart disease. Int J Cardiol. 2010 Feb 18;139(1):95-7. doi: 10.1016/j.ijcard.2008.06.076. Epub 2008 Aug 22. PubMed PMID: 18722681.
AÑO: 2010; IF: 6.802
|